A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy
This study is for participants with Non-small Cell Lung Cancer that has spread or has reoccurred after failure of Chemotherapy and Immunotherapy
Carcinoma, Non-small Cell Lung Cancer
BIOLOGICAL: nivolumab|BIOLOGICAL: ipilimumab|DRUG: cabozantinib|BIOLOGICAL: docetaxel|BIOLOGICAL: ramucirumab|DRUG: lucitanib
Overall Reponse Rate (ORR) using RECIST 1.1 per Blinded Independent Central Review (BICR) assessment, approximately 33 months
Overall Survival (OS), Up to 5 Years|Duration of Response (DOR) by BICR using RECIST 1.1, approximately 33 months|Progression-Free Survival (PFS) by BICR using RECIST 1.1, Up to 5 Years|Incidence of Adverse Events (AEs), Up to 5 Years|Incidence of Serious Adverse Events (SAEs), Up to 5 Years|Incidence of Select AEs, Up to 5 Years
This study is for participants with Non-small Cell Lung Cancer that has spread or has reoccurred after failure of Chemotherapy and Immunotherapy